Mental Health Research
Over 70 million people worldwide suffer from treatment-resistant PTSD. We believe serotonergic psychedelics represent one of the most promising frontiers in neuropsychiatric treatment — and we are funding the research to prove it.
Our Approach
We fund peer-reviewed clinical studies exploring novel treatments for PTSD and depression. Our focus is on psychedelic-assisted therapies — substances like DMT, psilocybin, and ketamine that have shown significant promise in patients who have not responded to conventional treatments.